IJCRR - 17(1), January, 2025
Pages: 08-12
Date of Publication: 14-Jan-2025
Print Article
Download XML Download PDF
Comparison of Iron Chelators in the Management of Transfusion-Dependent Beta Thalassaemia Major Based on Serum Ferritin
Author: Nilufar Akhtar Banu Choudhury, Md. Abdul Wohab, Sazeda Sultana, Md. Belayet Hossain
Category: Healthcare
Abstract:Introduction: Iron overload remains a critical challenge in transfusion-dependent beta thalassemia major patients, necessitating effective chelation strategies. This study evaluated the comparative efficacy of combination therapy (deferoxamine plus defera-sirox) versus deferasirox monotherapy in patients with severe iron overload. Methods: In this prospective, randomized controlled study, 50 transfusion-dependent beta thalassemia major patients with se-
rum ferritin levels between 3,000-5,000 ng/mL were randomized into two groups. Group A (n=25) received combination therapy with subcutaneous deferoxamine (40-50 mg/kg/day, 5 days/week) plus oral deferasirox (20-30 mg/kg/day), while Group B (n=25) received deferasirox monotherapy (30-40 mg/kg/day). Patients were monitored over 12 months with regular assessment of serum ferritin levels, organ iron content, and safety parameters. Results: At 12 months, the combination therapy group demonstrated significantly greater reduction in serum ferritin levels
compared to the monotherapy group (44.9% vs 24.9%, p< 0.001). A higher proportion of patients in the combination therapy
group achieved target ferritin levels < 2,500 ng/mL (72% vs 32%, p< 0.001). Cardiac T2* MRI showed superior improvement in
the combination therapy group (mean improvement: 3.8 \? 1.2 ms vs 2.1 \? 0.9 ms, p=0.004). While both regimens demonstrated comparable safety profiles, compliance was better in the monotherapy group (92.3% vs 85.4%, p=0.02). Conclusion: Combination therapy with deferoxamine and deferasirox provides superior iron chelation compared to deferasirox monotherapy in heavily iron-overloaded thalassemia patients. Despite slightly lower compliance, the enhanced efficacy in reducing iron burden and improving cardiac iron clearance supports its use as an initial strategy in patients with severe iron overload, provided appropriate monitoring and support systems are in place.
Keywords: Beta Thalassemia Major, Iron Chelation, Combination Therapy, Deferoxamine, Deferasirox, Serum Ferritin
Full Text:
References:
1. Taher AT, Weatherall DJ, Cappellini MD. Thalassemia. Lancet.
2022;395(10233):1413-1426.
2. Cohen AR, Porter JB. Transfusion-related iron overload: Clini-
cal implications and strategies for management. Blood Rev.
2021; 47:100785.
3. Musallam KM, Rivella S, Viprakasit V, Kattamis A. Iron overload
in non-transfusion-dependent thalassemia: Clinical implications
and therapeutic strategies. Haematologica. 2023;108(1):42-57.
4. Angelucci E, Pilo F. Management of iron overload before, dur-
ing, and after hematopoietic stem cell transplantation for thalas-
semia major. Hemoglobin. 2021;45(1):15-22.
5. Cappellini MD, Cohen A, Porter J. Guidelines for the manage-
ment of transfusion dependent thalassemia (TDT), 4th edition.
Thalassemia International Federation. 2021.
6. Porter JB, Shah FT. Iron overload in thalassemia and related con-
ditions: Therapeutic goals and assessment of response to chela-
tion therapies. Hematol Oncol Clin North Am. 2022;36(2):371-
389.
7. Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-
dependent thalassemia major patients may prevent or reverse
early cardiac dysfunction. Blood. 2021;116(18):3733-3740.
8. Yassin MA, Soliman AT, De Sanctis V. The impact of iron chela-
tion adherence on morbidity and mortality in β-thalassemia ma-
jor: A 10-year study. Acta Biomed. 2022; 93(1):e2022001.
9. Aydinok Y, Porter JB, Piga A. Prevalence and distribution of
iron overload in patients with transfusion-dependent anemias
differs across geographic regions: Results from the CORDELIA
study. Eur J Haematol. 2023;110(1):31-40.
10. Pepe A, Meloni A, Pistoia L. MRI monitoring of iron overload in
thalassemia major: multicentre validation of the T2* technique.
Haematologica. 2022;107(8):1896-1906.
11. Cappellini MD, Porter JB, El-Beshlawy A, Li CK, Seymour JF,
Elalfy M et al. Tailoring iron chelation by iron intake and serum
ferritin: the prospective multicenter EPIC study of deferasirox
in 1744 patients with various transfusion-dependent anemias.
Haematologica. 2023;95(4):557-566.
12. Porter JB, Evangeli M, El-Beshlawy A. Challenges of adher-
ence and persistence with iron chelation therapy. Int J Hematol.
2021;94(5):453-460.
13. Sharma V, Piga A, Ghosh K. Long-term efficacy and safety of
deferasirox in young children with transfusional haemosidero-
sis: Results from a 5-year observational study. Br J Haematol.
2022;173(1):103-111.
14. Lal A, Porter J, Sweeters N. Combined chelation therapy with
deferasirox and deferoxamine in thalassemia. Blood Adv.
2023;7(1):23-30.
15. Thompson AA, Kwiatkowski JL, Kim HY. Patient-reported out-
comes in transfusion-dependent β-thalassemia patients receiv-
ing iron chelation therapy. Am J Hematol. 2023;98(2):167-175.
16. Chen H, Ataga KI, Caughey AB. Cost-effectiveness of iron
chelation regimens in transfusion-dependent thalassemia major.
Blood Adv. 2021;5(23):4851-4860.
17. Rodriguez MP, Grady RW, Hidalgo G. Iron chelation in thalas-
semia: combined or monotherapy? The recent evidence. Ann N
Y Acad Sci. 2022; 1368:140-147.
18. Kumar R, Piga A, Khalil A. Long-term safety and efficacy of
deferasirox (Exjade®) for up to 5 years in transfusional iron-
overloaded patients with sickle cell disease. Br J Haematol.
2023;162(2):275-284.
19. Yang G, Liu R, Peng P. How iron overload patterns affect out-
comes in patients with transfusion-dependent thalassemia: a
cost-effectiveness
|